According to Arizton’s latest research report, the CRDMO market is growing at a CAGR of 9% during 2023-2029.
To Know More, Click: https://www.arizton.com/market-reports/crdmo-market
Report Summary
Market Size (2029): $328.90 Billion
Market Size (2023): $196.14 Billion
CAGR (2023-2029): 9%
Historic Year: 2020-2022
Base Year: 2023
Forecast Year: 2024-2029
Market Segmentation: Functions, Modality, and Geography
Geographic Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa
The CRDMO market is characterized by a mix of large, integrated service providers and smaller, specialized companies that focus on niche segments such as biologics, gene therapies, and small molecules. While this diversity creates a fragmented landscape, there is a growing trend of consolidation, with larger CRDMOs acquiring specialized firms to expand their service offerings and technological expertise. For example, WuXi AppTec's acquisition of OXGENE enhanced its gene therapy capabilities. Larger companies providing end-to-end solutions are gaining significant market share, attracting pharmaceutical and biotech firms seeking streamlined processes. Meanwhile, niche CRDMOs focusing on advanced therapeutic areas are flourishing but could become acquisition targets. As the market evolves, the increasing demand for integrated services and specialized expertise in emerging therapies will shape the competitive landscape, with companies that balance innovation, integration, and specialization leading the way.
Benefits of Clinical Development and Trial Supply Management for the CRDMO Market
Clinical development and trial supply management are crucial elements driving growth in the Contract Research, Development, and Manufacturing Organization (CRDMO) market. The expanding global pharmaceutical and biopharmaceutical industries are increasingly reliant on CRDMOs to manage the complex logistics of clinical trials, from early-phase testing to commercialization. This growing demand for clinical trial materials (CTMs) presents significant opportunities for CRDMOs, especially those providing tailored services such as small-batch production, drug formulation, and packaging.
CRDMOs are benefiting from the increased need for strict cGMP-compliant processes that ensure the integrity of clinical trial supplies. Their ability to efficiently scale drug substances and maintain consistent quality across batches is vital for successful clinical testing. Moreover, CRDMOs help streamline the clinical development process by handling regulatory compliance, packaging, labeling, and distribution logistics, which enhances the overall efficiency of drug development.
Technological advancements such as cold chain logistics, serialization, and real-time tracking are transforming the supply chain management process, ensuring the timely and safe delivery of temperature-sensitive materials across multiple trial sites. CRDMOs' expertise in these areas supports the accelerated pace of clinical trials, minimizing delays. Additionally, CRDMOs are capitalizing on opportunities in emerging markets like Asia-Pacific, where the growing demand for clinical trial services offers substantial growth potential, driving the CRDMO market further forward.
Europe Gaining Momentum in the CRDMO Market
Europe is gaining significant momentum in the CRDMO market, accounting for 25.00% of the global market share with a projected CAGR of 9.77%. This growth is driven by the region's strong pharmaceutical and biotech industries, a supportive regulatory environment, and increasing demand for outsourced drug development and manufacturing services. Key markets such as the UK, Germany, and France are leading the way, with the UK focusing on R&D and advanced therapies like gene and cell therapy, while Germany’s strong manufacturing base attracts global pharmaceutical companies.
The growing demand for biologics and complex medicines is further fueling CRDMO market expansion in Europe, as CRDMOs focus on biomanufacturing capabilities. Countries like Ireland and the Netherlands are investing heavily to produce biologics, biosimilars, and advanced therapies, aligning with the rising demand for personalized medicine and the treatment of chronic diseases.
Additionally, the increasing trend of outsourcing in the pharmaceutical industry, especially among smaller biotech companies, has boosted the need for CRDMO services. By partnering with both large pharmaceutical firms and smaller biotechs, European CRDMOs are well-positioned to provide tailored solutions across various stages of drug development. With ongoing investment in biomanufacturing and a focus on regulatory compliance, Europe’s CRDMO market is set for continued growth, meeting the demand for innovative therapies and specialized services.
Recent Developments, Mergers & Acquisitions in the Global CRDMO Market
Recent Developments:
- In 2023, Lonza expanded its CRDMO capabilities by opening a new development and manufacturing facility dedicated to cell and gene therapies, enhancing support for advanced therapeutic modalities.
- Catalent, a prominent CRDMO, launched a comprehensive suite of services for the development and manufacturing of mRNA vaccines, aligning with the increasing demand for RNA-based therapies.
Mergers and Acquisitions:
- In 2021, WuXi AppTec acquired Oxyrane UK, further strengthening cell and gene therapy service offerings for global customers.
- Curia acquired LakePharma, a biologics-focused CRO and CDMO, in March 2021 to enhance its biopharmaceutical development and manufacturing capacity.
- Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development in 2021.
Why Vendors Should Invest in the CRDMO Market
Investing in the CRDMO market offers significant opportunities due to the rapid growth of the pharmaceutical and biopharmaceutical sectors. With rising demand for novel therapies, CRDMOs play a crucial role in drug development and manufacturing, offering services like formulation, small-batch production, and logistics. The shift toward outsourcing by pharmaceutical companies enhances the demand for integrated CRDMO solutions, driving market growth. Technological advancements, including cold chain logistics and real-time tracking, improve operational efficiency. Additionally, emerging markets like Asia-Pacific provide further growth potential, making CRDMOs an attractive investment due to their essential role in global drug development.
Buy this Research @ https://www.arizton.com/market-reports/crdmo-market
Key Company Profiles
- Aragen Life Sciences Ltd.
- Catalent, Inc
- Jubilant Biosys Ltd.
- Lonza
- Sai Life Sciences Limited
- Syngene International Limited
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- BioDuro-Sundia
- WuXi Biologics
- PHT Industries
- Esco Aster Pte. Ltd
- Charles River Laboratories
- Siegfried Holding AG
- Recipharm AB
- Cambrex Corporation
- Piramal Pharma Limited
- Rentschler Biopharma SE
- Asymchem Inc.
- AGC Biologics
- Curia Global, Inc.
- Quotient Sciences
- Aurigene Pharmaceutical Services Ltd.
- MabPlex International Co., Ltd.
- CordenPharma
- Bluepharma
- Angelini S.p.a.
- Adragos Pharma
- LAXAI
- FUJIFILM Diosynth Biotechnologies
- Pharmaron
- Anthem Biosciences
Market Segmentation
Functions
- Clinical Development & Supplies
- Commercial Manufacturing
- Discovery
- Preclinical Development
Modality
- Small Molecule
- Biologics
Geography
APAC
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Singapore
Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- Switzerland
- Belgium
North America
- The U.S.
- Canada
Middle East & Africa
- The UAE
- Saudi Arabia
- South Africa
Latin America
- Brazil
- Mexico
- Argentina
Key Questions Answered in the Report:
What is the growth rate of the global CRDMO market?
How big is the global CRDMO market?
What are the significant trends in the CRDMO market?
Which region dominates the global CRDMO market share?
Who are the key players in the global CRDMO market?
Check Out Some of the Top Selling Reports of Your Interest:
Global Biopharmaceutical Contract Manufacturing Market - Focused Insights 2024-2029
https://www.arizton.com/market-reports/biopharmaceutical-contract-manufacturing-market
IVD Contract Manufacturing Market - Global Outlook & Forecast 2024-2029
https://www.arizton.com/market-reports/ivd-contract-manufacturing-market
Why Arizton?
100% Customer Satisfaction
24x7 availability – we are always there when you need us
200+ Fortune 500 Companies trust Arizton's report
80% of our reports are exclusive and first in the industry
100% more data and analysis
1500+ reports published till date
Post-Purchase Benefit
- 1hr of free analyst discussion
- 10% off on customization
About Us:
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email:Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/crdmo-market
